US2019328834A1PendingUtilityA1

Arthrofactin for the treatment of acne

Assignee: OREALPriority: Dec 22, 2016Filed: Dec 15, 2017Published: Oct 31, 2019
Est. expiryDec 22, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61P 17/10A61K 38/12A61K 9/0014
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a mixture of arthrofactin or of a composition containing it and to the use thereof for the treatment of acneic skin.

Claims

exact text as granted — not AI-modified
1 . An arthrofactin mixture comprising
 (i) arthrofactin A of formula (I) below:
   R 1 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Asp 11   (I),
 
   in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Asp 11  amino acid residue, and 
 R 1  represents the group of formula (I′) below: 
   
       
         
           
           
               
               
           
         
         
           
             where R 1 ′ is a saturated alkyl chain of 5 to 8 carbon atoms; and 
           
         
         (ii) at least one derivative of arthrofactin A, said derivative being of formula (II) below:
   R-Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Xaa 7 -Xaa 8 -Xaa 9 -Xaa 10 -Xaa 11   (II)
 
 
         in which
 Xaa 1 , Xaa 4 , Xaa 5 , Xaa 7 , Xaa 9  and Xaa 10  each represent, independently, D-Leu, L-Leu, D-Ile or L-Ile, 
 Xaa 2  and Xaa 11  each represent, independently, D-Asp, L-Asp, D-Glu or L-Glu, 
 Xaa 3  represents D-Thr, L-Thr, D-allo-Thr or L-allo-Thr, 
 Xaa 6  and Xaa 8  each represent, independently, D-Ser, L-Ser, D-Gln or L-Gln, 
 the hydroxyl group of the Xaa 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the Xaa 11  amino acid residue, and 
 R represents the group of formula (II′) below: 
 
       
       
         
           
           
               
               
           
         
         
           
             where R′ is an alkyl chain of 5 to 9 carbon atoms, optionally comprising at least one unsaturation; 
           
         
       
       for the treatment of acneic skin. 
     
     
         2 . The mixture according to  claim 1 , in which said acneic skin has imperfections related to  Propionibacterium acnes.    
     
     
         3 . The mixture according to  claim 1 , for inhibiting the growth of  Propionibacterium acnes.    
     
     
         4 . The mixture according to  claim 1 , in which R 1 ′ is a saturated alkyl chain of 7 carbon atoms. 
     
     
         5 . The mixture according to  claim 1 , in which said at least one derivative of arthrofactin A is chosen from the group consisting of arthrofactin B, arthrofactin C, arthrofactin D and mixtures thereof,
 arthrofactin B being of formula (III) below:
   R 1 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Glu 11   (III),
 
 in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Glu 11  amino acid residue, and 
 
   arthrofactin C being of formula (IV) below:
   R 2 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Asp 11   (IV),
 
 in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Asp 11  amino acid residue, and 
 R 2  represents the group of formula (IV′) below: 
 
   
       
         
           
           
               
               
           
         
         
           where R 2 ′ is an alkyl chain of 9 carbon atoms comprising exactly one unsaturation; 
         
         arthrofactin D being of formula (V) below:
   R 3 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Asp 11   (V),
 
 in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Asp 11  amino acid residue, and 
 R 3  represents the group of formula (V′) below: 
 
 
       
       
         
           
           
               
               
           
         
         
           where R 3 ′ is a saturated alkyl chain of 9 carbon atoms. 
         
       
     
     
         6 . The mixture according to  claim 1 , in which said arthrofactin mixture comprises
 (iii) arthrofactin A of formula (IA) below:   
       
         
           
           
               
               
           
         
         (iv) at least one derivative of arthrofactin A chosen from the compounds of formula (IIA), (IIB) and/or (IIC) of formula(e) below: 
       
       
         
           
           
               
               
           
         
       
     
     
         7 . The mixture according to  claim 1 , in which said at least one derivative of arthrofactin A is a mixture of said compounds of formula (IIA), (IIB) and (IIC). 
     
     
         8 . The mixture according to  claim 1 , in which the arthrofactin mixture predominantly comprises arthrofactin A. 
     
     
         9 . The mixture according to  claim 1 , in which said arthrofactin mixture is capable of being obtained by fermentation with the  Pseudomonas  sp. MIS38 strain. 
     
     
         10 . A composition comprising the arthrofactin mixture as defined in  claim 1 , for the treatment of acneic skin. 
     
     
         11 . The composition according to  claim 10 , said composition being a dermatological composition. 
     
     
         12 . The composition according to  claim 10 , in which said acneic skin has imperfections related to  P. acnes.    
     
     
         13 . The composition according to  claim 10 , for inhibiting the growth of  Propionibacterium acnes.    
     
     
         14 . The mixture according to  claim 3 , in which said at least one derivative of arthrofactin A is chosen from the group consisting of arthrofactin B, arthrofactin C, arthrofactin D and mixtures thereof,
 arthrofactin B being of formula (III) below:
   R 1 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Glu 11   (III),
 
   
       in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Glu 11  amino acid residue, and 
 R 1  is as defined in  claim 1 ;
 arthrofactin C being of formula (IV) below:
   R 2 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Asp 11   (IV),
 
 
 in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Asp 11  amino acid residue, and 
 
 
 R 2  represents the group of formula (IV′) below: 
 
       
         
           
           
               
               
           
         
         
           where R 2 ′ is an alkyl chain of 9 carbon atoms comprising exactly one unsaturation; 
         
         arthrofactin D being of formula (V) below:
   R 3 -D-Leu 1 -D-Asp 2 -D-allo-Thr 3 -D-Leu 4 -D-Leu 5 -D-Ser 6 -L-Leu 7 -D-Ser 8 -L-Ile 9 -L-Ile 10 -L-Asp 11   (V),
 
 
         in which
 the hydroxyl group of the D-allo-Thr 3  amino acid residue forms an ester bond with the C-terminal carboxyl group of the L-Asp 11  amino acid residue, and 
 
         R 3  represents the group of formula (V′) below: 
       
       
         
           
           
               
               
           
         
       
       where R 3 ′ is a saturated alkyl chain of 9 carbon atoms. 
     
     
         15 . The mixture according to  claim 4 , in which said arthrofactin mixture comprises
 (iii) arthrofactin A of formula (IA) below:   
       
         
           
           
               
               
           
         
         (iv) at least one derivative of arthrofactin A chosen from the compounds of formula (IIA), (IIB) and/or (IIC) of formula(e) below: 
       
       
         
           
           
               
               
           
         
       
     
     
         16 . The mixture according to  claim 4 , in which said arthrofactin mixture comprises
 (iii) arthrofactin A of formula (IA) below:   
       
         
           
           
               
               
           
         
         (iv) at least one derivative of arthrofactin A chosen from the compounds of formula (IIA), (IIB) and/or (IIC) of formula(e) below: 
       
       
         
           
           
               
               
           
         
       
     
     
         17 . The mixture according to  claim 4 , in which said at least one derivative of arthrofactin A is a mixture of said compounds of formula (IIA), (IIB) and (IIC). 
     
     
         18 . The mixture according to  claim 5 , in which said at least one derivative of arthrofactin A is a mixture of said compounds of formula (IIA), (IIB) and (IIC). 
     
     
         19 . The mixture according to  claim 6 , in which said at least one derivative of arthrofactin A is a mixture of said compounds of formula (IIA), (IIB) and (IIC). 
     
     
         20 . The mixture according to  claim 4 , in which the arthrofactin mixture predominantly comprises arthrofactin A.

Join the waitlist — get patent alerts

Track US2019328834A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.